(NASDAQ: IDYA) Ideaya Biosciences's forecast annual revenue growth rate of 87.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.33%.
Ideaya Biosciences's revenue in 2026 is $36,535,000.On average, 17 Wall Street analysts forecast IDYA's revenue for 2026 to be $4,348,548,427, with the lowest IDYA revenue forecast at $1,460,958,334, and the highest IDYA revenue forecast at $8,680,755,471. On average, 16 Wall Street analysts forecast IDYA's revenue for 2027 to be $12,579,964,208, with the lowest IDYA revenue forecast at $5,685,641,010, and the highest IDYA revenue forecast at $20,278,786,269.
In 2028, IDYA is forecast to generate $23,760,757,915 in revenue, with the lowest revenue forecast at $11,135,347,257 and the highest revenue forecast at $41,772,056,400.